ETON vs SRPT
ETON: Eton Pharmaceuticals is a specialty drug company dedicated to acquiring and commercializing a diverse portfolio of therapies for rare diseases. SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy.
Side-by-side fundamentals
| Metric | ETON | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $64.43 | $18.92 | |
| Market cap as of 2026-08-26 | $1.8B | $2.0B | |
| PEG as of 2026-08-26 | n/a | -21.22 | |
| Net margin as of 2026-08-26 | -1.7% | -6.9% | ETON higher |
| Gross margin as of 2026-08-26 | +54.8% | +67.5% | SRPT higher |
| Operating margin as of 2026-08-26 | +2.4% | -6.4% | ETON higher |
| ROE as of 2026-08-26 | -5.7% | -10.0% | ETON higher |
| ROA as of 2026-08-26 | -1.5% | -4.1% | ETON higher |
| Debt / equity as of 2026-08-26 | 1.00 | 0.55 | SRPT lower |
| Revenue growth (YoY) as of 2026-08-26 | +79.9% | -20.4% | ETON higher |
| Revenue CAGR (3y) SEC XBRL | +55.5% | +33.1% | ETON higher |
| Beta as of 2026-08-26 | 0.89 | 0.32 | |
| 1-year return as of 2026-08-24 close | +272.4% | +4.8% | ETON higher |
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.